Discontinuation for Oral Anticoagulants in Patients With Atrial Fibrillation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

360 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-04-04

Study Completion Date

2020-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the discontinuation rates for vitamin K antagonists and for direct oral anticoagulants during their first year

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin)

NCT03596502

Atrial Fibrillation Ischemic Stroke Systemic Embolization +3 more

COMPLETED

Therapy With New Oral Anticoagulants

NCT02222090

Atrial Fibrillation Non-valvular Atrial Fibrillation

UNKNOWN

Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)

NCT03568916

Atrial Fibrillation Ischemic Stroke Systemic Embolization +3 more

COMPLETED

A Phase III Study of Apixaban in Patients With Atrial Fibrillation

NCT00496769

Atrial Fibrillation

COMPLETED PHASE3

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

NCT00580216

Atrial Fibrillation

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to compare the discontinuation rates for vitamin K antagonists and for direct oral anticoagulants during their first year of use after their initiation during hospitalization in patients covered by our health insurance plan.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Auricular Fibrillation Anticoagulant Drugs

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DOAC

Direct oral anticoagulant

No interventions assigned to this group

OAC

Vitamin K anticoagulant

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient older than 18 years of age covered by our Health Care Insurance Plan.
2. Indication for oral anticoagulation with an expected duration of use of no less than 1 year.

Exclusion Criteria

1. Refusal to take part.
2. Use of oral anticoagulants within 6 months prior to admission.
3. Presence of mechanical prosthetic valve.
4. Chronic renal failure with creatinine clearance \<30 mL/min (estimated using the MDRD formula).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No